Polosa R, Milazzo V L, Magrì S, Pagano C, Paolino G, Santonocito G, Prosperini G, Crimi N
Istituto Malattie Apparato Respiratolio Universita' di Catania, Italy.
Eur Respir J. 1997 Apr;10(4):866-71.
When administered by inhalation, bradykinin provokes dose-related bronchoconstriction in asthmatic subjects by a mechanism believed to involve activation of sensory nerve endings. However, little is known of the change in airway responsiveness to bradykinin after cyclo-oxygenase blockade. The aim of the present study was to investigate the effect of the potent cyclo-oxygenase inhibitor, lysine acetylsalicylate (L-ASA), administered by inhalation, on bradykinin-induced bronchoconstriction in a group of 12 asthmatic subjects. The subjects attended the laboratory on four separate occasions to receive nebulized L-ASA (solution of 90 mg x mL(-1)) or matched placebo (glycine, solution of 30 mg x mL(-1)) 15 min prior to bronchoprovocation tests with bradykinin and methacholine in a randomized, double-blind order with at least a 5 day interval. Changes in airway calibre were followed as forced expiratory volume in one second (FEV1), and responsiveness to agonists was expressed as the provocative concentration causing a 20% fall in FEV1 from baseline (PC20). Administration both of L-ASA and glycine solution caused a small but significant acute fall in FEV1 from baseline, with gradual recovery within 20 min. When compared to placebo, inhaled L-ASA reduced the airway responsiveness to bradykinin in 11 of the 12 subjects studied, the geometric mean (range) values for PC20 bradykinin increasing significantly (p<0.001) by 1.7 doubling dose from 0.55 (0.11-5.05) to 1.72 (0.26-6.05) mg x mL(-1) after placebo and L-ASA, respectively. No significant change in airway responsiveness to methacholine was recorded after L-ASA. It is concluded that administration of lysine acetylsalicylate by inhalation protects the asthmatic airways against bradykinin-induced bronchoconstriction, thus suggesting that endogenous prostaglandins may play a contributory role in the bronchoconstriction to kinins in human asthma.
通过吸入给药时,缓激肽会通过一种被认为涉及感觉神经末梢激活的机制,在哮喘患者中引发剂量相关的支气管收缩。然而,关于环氧化酶阻断后气道对缓激肽反应性的变化,人们知之甚少。本研究的目的是调查强效环氧化酶抑制剂赖氨酸乙酰水杨酸酯(L-ASA)经吸入给药,对一组12名哮喘患者缓激肽诱导的支气管收缩的影响。受试者在四个不同时间到实验室,在使用缓激肽和乙酰甲胆碱进行支气管激发试验前15分钟,以随机、双盲顺序接受雾化的L-ASA(90 mg x mL(-1)溶液)或匹配的安慰剂(甘氨酸,30 mg x mL(-1)溶液),间隔至少5天。以一秒用力呼气量(FEV1)跟踪气道口径变化,对激动剂的反应性以引起FEV1从基线下降20%的激发浓度(PC20)表示。L-ASA和甘氨酸溶液给药均导致FEV1较基线有小幅但显著的急性下降,并在20分钟内逐渐恢复。与安慰剂相比,吸入L-ASA使12名受试患者中的11名气道对缓激肽的反应性降低,安慰剂和L-ASA给药后,缓激肽PC20的几何平均(范围)值从0.55(0.11 - 5.05)显著增加(p<0.001)1.7倍剂量至1.72(0.26 - 6.05)mg x mL(-1)。L-ASA给药后,气道对乙酰甲胆碱的反应性未记录到显著变化。结论是,吸入赖氨酸乙酰水杨酸酯可保护哮喘气道免受缓激肽诱导的支气管收缩,因此表明内源性前列腺素可能在人类哮喘中对激肽引起的支气管收缩起促成作用。